Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Audio By Carbonatix

PALO ALTO, Calif.--(BUSINESS WIRE)--Jan 29, 2026--

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Source: Guardant Health, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260129040273/en/

CONTACT: Investor Contact:

Zarak Khurshid

[email protected] Contact:

Meaghan Smith

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Guardant Health, Inc.

Copyright Business Wire 2026.

PUB: 01/29/2026 04:05 PM/DISC: 01/29/2026 04:05 PM

http://www.businesswire.com/news/home/20260129040273/en